We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
126
Amarin Corp
AMRN
$300M
$826K 0.01%
10,243
-7,257
-41% -$451K
MRNS
127
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$778K 0.01%
141,900
– –
ALIM
128
DELISTED
Alimera Sciences
ALIM
$348K ﹤0.01%
16,667
– –
XTNT icon
129
Xtant Medical Holdings
XTNT
$59.1M
$314K ﹤0.01%
39,620
– –
XYLO
130
DELISTED
Xylo Technologies
XYLO
$131K ﹤0.01%
375
– –
ACAD icon
131
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-1,169,000
Closed -$40.2M
BMY icon
132
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-100,000
Closed -$5.44M
BMY icon
133
PUT
Bristol-Myers Squibb
BMY
$130B
– –
-200,000
Closed -$10.9M
CLSD
134
DELISTED
Clearside Biomedical
CLSD
– –
-20,000
Closed -$2.38M
CNC icon
135
Centene
CNC
$31.3B
– –
-3,311,400
Closed -$118M
COO icon
136
Cooper Companies
COO
$14.2B
– –
-763,200
Closed -$38.1M
EXAS
137
DELISTED
Exact Sciences
EXAS
– –
-602,900
Closed -$14.2M
SRPT icon
138
Sarepta Therapeutics
SRPT
$1.65B
– –
-1,054,300
Closed -$31.2M
THC icon
139
Tenet Healthcare
THC
$22.4B
– –
-5,352,000
Closed -$94.8M
LUMO
140
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-22,222
Closed -$4.82M
EGRX
141
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-671,000
Closed -$55.7M
ALXN
142
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-50,000
Closed -$6.06M
WMGI
143
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-250,000
Closed -$7.78M
BCR
144
DELISTED
CR Bard Inc.
BCR
– –
-58,000
Closed -$14.4M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.